Fortrea Holdings Inc. is a contract research organization (CRO) managing Phase I through IV clinical studies, clinical pharmacology, and market access solutions for biopharma and MedTech companies across roughly 100 countries. The company emerged from the clinical research heritage of Covance and Labcorp - more than 30 years of institutional knowledge - and now operates with over 14,500 employees globally.
For security practitioners, the threat surface here is broad and high-stakes. Clinical trial data, patient safety systems, and proprietary pharmacology information are prime targets - think nation-state actors interested in drug pipeline intelligence, ransomware groups eyeing operational disruption, and insider threats in a workforce of this scale. The organization handles regulated health data across nearly every major jurisdiction, meaning compliance regimes like HIPAA, GDPR, and country-specific clinical trial regulations define the baseline for any security program.
Fortrea's technical domains span clinical research operations, pharmacology platforms, and market access infrastructure - each with distinct data flows, third-party integrations, and attack vectors. The company's culture signals emphasize accountability and integrity, which at least suggests a security team that can push governance without fighting upstream. With patients' safety cited as a core priority, security is not a back-office function here - it is directly coupled to clinical outcomes.
